Roche pays $200m for Vaccibody's cancer vaccine drug

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tu

Regeneron pairs with BioNTech on melanoma immunotherapy

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other ch

Transgene starts trials of ‘digital’ cancer vaccine with NEC

UK startup Ervaxx targets ‘dark matter’ of human genome

Invitation from Chair of this year’s Immuno-Oncology Confere...

Invitation from Chair of Immuno-Oncology Conference

Scancell to collaborate with charity CRUK on cancer vaccine

Trial will combine cancer vaccine with checkpoint inhibitor